The city's axess sexual health service is piloting a new online platform that will deliver preventative HIV medication PrEP ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy ...

South Africa's Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

Lenacapavir is a revolutionary long-acting injectable drug that offers six months of protection with just two annual ...

We finally have the technology, infrastructure, and the political will to end the US HIV epidemic, write the Brown University ...

Some lawmakers and advocates are increasingly uncertain whether critical HIV and AIDS services will survive the federal government’s funding fight. The GOP’s House-passed budget bill seeks to cut ...

The South African Health Products Regulatory Authority (SAHPRA) has registered the drug Lenacapavir, which the World Health ...

An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa's medicines regulator. The approval helps to clear the way for a limited public sector ...